€55.99
This product ships to the US and Canada using FedEx
Ipamorelin is a fairly short-sequence peptide made of four amino acids only. It is known for its growth hormone (GH) releasing effect from the pituitary gland and improvements in lean muscle mass and weight loss, with little known effect on thyroid-stimulating hormone, luteinizing hormone, prolactin, follicle-stimulating hormone, ACTH, or cortisol release [1]. Improvements in GH levels from GHRP peptides are known to have a wide range of clinical benefits including body fat and weight loss, improved skin elasticity and function, decreased cortisol production, and improved energy and sleep for patients. Ipamorelin is often compared to GHRP 6 and GHRP 2 due to their similarities in the results they provide. Studies have shown multiple other positive effects of the Ipamorelin peptide, the below sections will outline some.
In one study Ipamorelin has shown its potential in reducing or even reversing the side effects from glucocorticoid use, which are commonly observed in inflammatory conditions ranging from cancer to autoimmune diseases. Glucocorticoids can lead to the loss of lean muscle tissue, intramuscular amino acids, and increased body fat. Ipamorelin’s pituitary gland stimulation may help to combat these effects according to this study [2].
One of the main negative effects of glucocorticoids is a condition called muscle wasting. Several studies on rats have demonstrated that ipamorelin administration after glucocorticoid treatment resulted in a decrease in amino acid wasting in the liver tissue and improved nitrogen balance in the muscles [2, 9].
Another negative effect well-known is that long-term use of glucocorticoids can result in a loss of bone density and increase the risk of bone fractures. Clinical studies have demonstrated that ipamorelin’s modulation of the pituitary gland can slow down or stop bone loss caused by corticosteroids and even increase and improve bone formation in rats exposed to ipamorelin [3]. Furthermore, ipamorelin has been shown to increase bone mineral density, enhancing the strength of existing and newly formed bones [4].
A study conducted on diabetic rats suggests that ipamorelin administration might stimulate insulin release by binding to the calcium channel found on pancreatic cells [5]. These effects on the pancreas could potentially assist in the development of preventative measures for type 2 diabetes.
The Ipamorelin peptide is known to bind to the ghrelin receptor, which is known to be increased in certain types of cancer and heart failure. It is speculated that ipamorelin could be used as a positron emission tomography (PET) probe to assist in the potential diagnosis of these medical conditions. One in vitro study supports this possibility and demonstrated the potential effectiveness of ipamorelin as a PET probe [6].
Post-operative ileus (POI) is an illness expressed by the temporary paralysis of the gastrointestinal system, resulting in the inability to ingest nutrients after eating. This condition is common after specific types of surgery, particularly abdominal surgery. Ipamorelin has been investigated for its potential to shorten the clinical recovery time and improve the ability to eat in individuals affected by POI [7, 8, 9].
SARMs should only be used under the direct supervision and direction of a trained and licensed medical doctor or a designated research authority. Sarmful strongly discourages the use of SARMs for performance enhancement in fields of various sports such as bodybuilding and achievement sports, etc.
S4 is an investigational compound still undergoing research and NOT yet FDA approved, nor it is a dietary supplement. Sarmful is solely a research chemical supplier specializing in sourcing and quality control. We are not medical doctors. Sarmful discourages strongly against “bro science” and peer consensus when making decisions about human health.
We do not encourage or condone consumer use of SARMs products, they are for research purposes only.
1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822.
2. Aagaard NK, Grøfte T, Greisen J, Malmlöf K, Johansen PB, Grønbaek H, Ørskov H, Tygstrup N, Vilstrup H. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. Growth Horm IGF Res. 2009 Oct;19(5):426-31. doi: 10.1016/j.ghir.2009.01.001. Epub 2009 Feb 23. PMID: 19231263.
3. Andersen NB, Malmlöf K, Johansen PB, Andreassen TT, Ørtoft G, Oxlund H. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001 Oct;11(5):266-72. doi: 10.1054/ghir.2001.0239. PMID: 11735244.
4. Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000 Jun;165(3):569-77. doi: 10.1677/joe.0.1650569. PMID: 10828840.
5. Adeghate E, Ponery AS. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro Endocrinol Lett. 2004 Dec;25(6):403-6. PMID: 15665799.
6. Fowkes MM, Lalonde T, Yu L, Dhanvantari S, Kovacs MS, Luyt LG. Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor. Eur J Med Chem. 2018 Sep 5;157:1500-1511. doi: 10.1016/j.ejmech.2018.08.062. Epub 2018 Aug 23. PMID: 30282322.
7. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014 Dec;29(12):1527-34. doi: 10.1007/s00384-014-2030-8. Epub 2014 Oct 21. PMID: 25331030.
8. Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol. 2012 Oct 19;4:149-55. doi: 10.2147/JEP.S35396. PMID: 27186127; PMCID: PMC4863553.
9. Ipamorelin Peptide: Exploring its Potential in Growth Hormone Stimulation and Health. Peptide Information (2023).
€55.99
